Cibc World Market Inc. Has $12.08 Million Stake in Bristol Myers Squibb Company $BMY

Cibc World Market Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 11.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 267,780 shares of the biopharmaceutical company’s stock after selling 35,340 shares during the quarter. Cibc World Market Inc.’s holdings in Bristol Myers Squibb were worth $12,077,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $25,000. Harbor Capital Advisors Inc. increased its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. Total Investment Management Inc. bought a new position in Bristol Myers Squibb during the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its holdings in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 700 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.3%

Shares of BMY opened at $59.78 on Friday. The company has a market capitalization of $121.69 billion, a P/E ratio of 17.33, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The business’s 50 day simple moving average is $55.16 and its 200-day simple moving average is $49.35. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the firm posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analyst Ratings Changes

A number of research firms have recently issued reports on BMY. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. HSBC restated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Citigroup lifted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.